[1]. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med,1965, 38:241–56.
[2]. Bragazzi MC, C V, Carpino G, et al. Cholangiocarcinoma: Epidemiology and risk factors: A Retrospective Study of 293 Patients. Transl Gastrointest Cancer, 2012, 1:21–32.
[3]. Zhi-yuan Mao, Xiao-chuan Guo, Dan Su. et al. Prognosis in cholangiocarcinoma patients. Med Sci Monit, 2015; 21: 2375-2381.
[4]. Michael E. Lidsky, William R. Jarnagin. Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer Center. Ann Gastroenterol Surg,2018, 2:304–312.
[5]. Nault JC. Reports from the International Liver Cancer Association (ILCA) congress 2014. J Hepatol, 2015; 62(2): 477–82 .
[6]. Salvador VB, Samrao P, Leytin A et al.Atypical presentation of an advanced obstructive biliary cancer without jaundice. Am J Case Rep, 2013; 14: 462–66
[7]. Miguel Angel Suarez-Munoz, Jose Luis Fernandez-Aguilar, Belinda Sanchez-Perez, et al. Risk factors and classifications of hilar cholangiocarcinoma. World J Gastrointest Oncol, 2013, 5(7): 132-138.
[8]. Hai-Jie Hu, Hui Mao, Anuj Shrestha, et al. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. World J Gastroenterol, 2016, 22(8): 2601-2610.
[9]. Norihisa Kimura, Yoshikazu Toyoki, Keinosuke Ishido, et al. Perioperative Blood Transfusion as a Poor Prognostic Factor After Aggressive Surgical Resection for Hilar Cholangiocarcinoma. J Gastrointest Surg ,2015,19:866–879.
[10]. Annemiek M. Dekker, Jimme K. Wiggers, Robert J. Coelen, et al. Perioperative blood transfusion is not associated with overall survival or time to recurrence after resection of perihilar cholangiocarcinoma. HPB,2016, 18:262–270.
[11]. Abd ElWahab M, El Nakeeb A, El Hanafy E, et al. Predictors of long-term survival after hepatic resection for hilar cholangiocarcinoma: a retrospective study of 5-year survivors. World J Gastrointest Surg. 2016;8:436–43.
[12]. Jang JY, Kim SW, Park DJ, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg, 2005;241:77–84.
[13]. Konstadoulakis MM, Roayaie S, Gomatos IP, et al. Aggressive surgical resection for hilar cholangiocarcinoma: is it justifified? Audit of a single center’s experience. Am J Surg,2008;196:160–9.
[14]. Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258:129–40.
[15]. Silva MA, Tekin K, Aytekin F, et al. Surgery for hilar cholangiocarcinoma:a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol, 2005;31:533–9.
[16]. Neuhaus P, Jonas S, Bechstein WO, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg;1999;230:808–18; discussion 819.
[17]. Nishio H, Nagino M, Nimura Y. Surgical management of hilar cholangiocarcinoma: the Nagoya experience. HPB Oxf. 2005;7:259–62.
[18].Zhi-yuan Mao ,Xiao-chuan Guo, Dan Su , et al.Prognostic Factors of Cholangiocarcinoma After Surgical Resection: A Retrospective Study of 293 Patients.Med Sci Monit, 2015; 21: 2375-2381
[19]. Cai, W.-K. et al. Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma. Int. J. Clin. Exp. Pathol. 2014;7, 7890–8.
[20].Sven H. Loosen , Christoph Roderburg, Katja L. Kauertz, et al.CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of Cholangiocarcinoma. Scientific Reports,2017; 7: 16975
[21]. Lin MS, Huang JX, Yu H. Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker. Int. J. Clin. Exp. Med. 2014;7, 744–50.
[22]. Ince, A. T. et al. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in diferentiating between malignant and benign biliary obstructions. Turk. J. Gastroenterol.2014; 25, 162–9.
[23]. Hirano S, Kondo S, Tanaka E, et al. Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality. J Hepatobiliary Pancreat ,2010;17:455-62.
[24].Tae Yoo,Sang-Jae Park,Sung-Sik Han,et al.Proximal Resection Margins: More Prognostic than Distal Resection Margins in Patients Undergoing Hilar Cholangiocarcinoma Resection. Cancer Res Treat. 2018;50(4):1106-1113.
[25]Volkan Öter,İlter Özer, Tahsin Dalgıç, et al.Results of positive proximal margin after resection for hilar cholangiocarcinoma: An analysis of 42 cases.Turk J Gastroenterol 2019; 30(1): 88-94.
[26].Hai‐Jie Hu, Yan‐Wen Jin, Anuj Shrestha,et al.Predictive factors of early recurrence after R0 resection of hilar cholangiocarcinoma: A single institution experience in China.Cancer Medicine. 2019;8:1567–1575.
[27].Yunfeng Gao, Dong Xu, Yu-Shen Wu, et al.Increasing negative lymph node count is independently associated with improved long-term survival in resectable perihilar Cholangiocarcinomas.Medicine ,2019; 98:15(e14943.
[28].Felice Giuliante, Francesco Ardito, Alfredo Guglielmi, et al.Association of Lymph Node Status With Survival in Patients After Liver Resection for Hilar Cholangiocarcinoma in an Italian Multicenter Analysis JAMA Surg. 2016;151(10):916-922.